{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:32:59Z","timestamp":1785879179145,"version":"3.56.0"},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,4,27]],"date-time":"2011-04-27T00:00:00Z","timestamp":1303862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Geriat Psychiatry"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to assess the safety and tolerability of extended\u2010release quetiapine fumarate (quetiapine XR) compared with quetiapine immediate\u2010release (quetiapine IR) in older patients with Alzheimer's disease with symptoms of psychosis and\/or agitation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a 6\u2010week, double\u2010blind, double\u2010dummy, randomised study. Of the 109 patients screened, 100 were randomised to receive quetiapine XR (<jats:italic>n<\/jats:italic>\u2009=\u200968) or quetiapine IR (<jats:italic>n<\/jats:italic>\u2009=\u200932), at doses of 50 and 25\u2009mg\/day, respectively. Treatment was escalated to 100\u2009mg\/day by Day 4. At Day 8, a flexible\u2010dose (50\u2010300\u2009mg\/day) period began when dose adjustment was made at the investigator's discretion. The primary variable was incidence and type of adverse events (AEs). Secondary variables included efficacy and other safety assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean daily doses were 143.6 and 142.0\u2009mg in the quetiapine XR and quetiapine IR groups, respectively. Ninety patients completed the study; only one withdrew (in the quetiapine XR group) because of an AE. Laboratory evaluations identified severe neutropaenia (one patient), mild neutropaenia (three patients) and eosinophilia (five patients); however, these were not reported, as AEs and confounding factors, such as patient age, concomitant illness and medication, made it difficult to determine any relationship to quetiapine treatment. Numerical improvements from baseline were seen across both treatment groups in Neuropsychiatric Inventory frequency \u00d7 severity total, Neuropsychiatric Inventory\u2010Nursing Home version, Cohen\u2013Mansfield Agitation Inventory, Clinical Global Impression\u2010Severity of Illness and Clinical Global Impression\u2010Improvement scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Quetiapine XR dosed up to 300\u2009mg\/day was generally well tolerated, with a similar profile to that of quetiapine IR. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/gps.2720","type":"journal-article","created":{"date-parts":[[2011,4,28]],"date-time":"2011-04-28T02:17:22Z","timestamp":1303957042000},"page":"296-304","source":"Crossref","is-referenced-by-count":21,"title":["Tolerability of extended\u2010release quetiapine fumarate compared with immediate\u2010release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and\/or agitation: a randomised, double\u2010blind, parallel\u2010group study"],"prefix":"10.1002","volume":"27","author":[{"given":"Peter Paul","family":"De Deyn","sequence":"first","affiliation":[{"name":"Department of Neurology Middelheim Hospital and Laboratory of Neurochemistry and Behaviour Department of Biomedical Sciences Institute Born Bunge University of Antwerp  Antwerp Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Eriksson","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals  Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Svensson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&amp;D  S\u00f6dert\u00e4lje Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Study 115 investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38369.459988.8F"},{"key":"e_1_2_8_3_1","first-page":"225","article-title":"Efficacy and tolerability of once\u2010daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD)","volume":"10","author":"Katila H","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0111"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31802eb4b7"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S104161020700484X"},{"key":"e_1_2_8_7_1","first-page":"239","article-title":"Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalised anxiety disorder (GAD)","volume":"10","author":"Magi K","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.5.596"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80085-5"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000196628.12010.35"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720507779939805"}],"container-title":["International Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fgps.2720","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/gps.2720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:30:10Z","timestamp":1695504610000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/gps.2720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,27]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1002\/gps.2720"],"URL":"https:\/\/doi.org\/10.1002\/gps.2720","archive":["Portico"],"relation":{},"ISSN":["0885-6230","1099-1166"],"issn-type":[{"value":"0885-6230","type":"print"},{"value":"1099-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,27]]}}}